Press Releases

InVivo Therapeutics Announces Symposium at 84th American Association for Neurological Surgeons Annual Scientific Meeting

Published: May 2, 2016

- Symposium to Feature Drs. Robert Langer, Domagoj Coric, and James Guest – CAMBRIDGE, Mass. (May 2, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will be holding a symposium at the 84th American Association for Neurological Surgeons (AANS) Annual Scientific Meeting on Monday, May 2, 2016 in Chicago, IL. InVivo will have several other engagement opportunities, including a Steering Committee meeting and an exhibitor booth. The symposium presentation is titled “Innovation in Spinal Cord Injury Treatment: The Investigational Neuro-Spinal Scaffold™ and Bioengineered Neural Trails™” and will feature presentations by three renowned key opinion leaders: Robert Langer, Sc.D., the David H. […]

View Article
InVivo Therapeutics Reports Conversion of a Fourth Patient Implanted with the Neuro-Spinal Scaffold™ in the INSPIRE Study

Published: April 26, 2016

- Four Out of First Six Patients Have Converted from Complete to Incomplete Spinal Cord Injury – CAMBRIDGE, Mass. (Apr 26, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the sixth-implanted patient in the INSPIRE study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. This is the fourth out of the first six patients (67%) with at least two months of follow up data to have had an AIS grade improvement. The Objective Performance Criterion (OPC), a measure of study success for the INSPIRE study, is defined as […]

View Article
InVivo Therapeutics to Present at Committee Roundtable on Biomedical Engineering Materials and Applications

Published: April 20, 2016

CAMBRIDGE, Mass. (April 20, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Thomas Ulich, M.D., Chief Scientific Officer, is scheduled to present at the Committee Roundtable on Biomedical Engineering Materials and Applications (BEMA) to be held on Monday, April 25, 2016 in Washington, D.C. The topic of the session is “Neuro Devices and Neuro Regeneration”. Dr. Ulich said, “We are looking forward to communicating InVivo’s program in the use of preformed and injectable scaffolds for the therapy of acute and chronic spinal cord injury.” BEMA is a roundtable initiative of the National Research Council of the National Academies […]

View Article
InVivo Therapeutics Expresses Condolences on Death of Eighth Patient Enrolled in INSPIRE Study

Published: April 19, 2016

- New Patient Enrolled in Study Died From Underlying Injuries – CAMBRIDGE, Mass. (Apr 19, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that an eighth patient enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) has died after injuries from a severe motor vehicle accident and unrelated to the investigational product. Travis Dumont, M.D., Director of the Neurovascular Program and Principal Investigator at Banner University Medical Center – Tucson performed the implantation on April 12, 2016, approximately 71 hours after the injury occurred. […]

View Article
InVivo Therapeutics Announces John A. McCarthy, Jr. to Not Stand for Re-election

Published: April 12, 2016

- Company Thanks for His Service – CAMBRIDGE, Mass. (April 12, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that John A. McCarthy, Jr. has decided not to stand for re-election to the Board of Directors at the Company’s 2016 Annual Meeting of the Stockholders. Mr. McCarthy is departing to devote more time to his role as Chief Executive Officer and a director of ZS Genetics, Inc. as well as his other business ventures. Mr. McCarthy will continue to serve as a director of the Company until the expiration of his term at the conclusion of the Company’s 2016 […]

View Article
InVivo Therapeutics Announces University of Virginia Health System as New Site for INSPIRE Study

Published: April 5, 2016

CAMBRIDGE, Mass. (April 5, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the University of Virginia (UVA) Health System in Charlottesville, VA has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The UVA Health System serves a large geographic area with a population base of approximately 800,000 in central Virginia and receives transfers from the rest of the state. “Spinal cord injury is a devastating condition with severe personal and societal costs. We are excited to participate in […]

View Article
InVivo Therapeutics Featured in Life Science Leader

Published: April 4, 2016

- Industry Veteran Wayne Koberstein Interviews CEO and Chairman Mark Perrin – CAMBRIDGE, Mass. (Apr 4, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company was featured in a Life Science Leader article titled “InVivo Therapeutics: Taking on Spinal Cord Injury” as part of The Enterprisers series. Wayne Koberstein, Executive Editor of the Life Science Leader magazine and 25-year veteran of the publishing industry, interviewed Mark Perrin, InVivo’s Chief Executive Officer and Chairman. Mr. Koberstein has interviewed and profiled over 200 top executives in pharmaceutical companies as well as influential regulatory and healthcare leaders around the world. In 2002, he won the […]

View Article
InVivo Therapeutics Announces Enrollment of Seventh Patient into The INSPIRE Study

Published: March 24, 2016

CAMBRIDGE, Mass. (Mar 24, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a seventh patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Carolinas Medical Center in Charlotte, NC. Domagoj Coric, M.D., of Carolina Neurosurgery and Spine Associates, Chief of Neurosurgery at the Carolinas Medical Center and a member of the INSPIRE Study Steering Committee, performed the implantation approximately 21 hours after the injury occurred. He and Dr. William Bockenek, Chief Medical Officer […]

View Article
InVivo Therapeutics Holdings Corp. Closes Exercise of Over-Allotment

Published: March 23, 2016

CAMBRIDGE, Mass. (March 23, 2016) – InVivo Therapeutics Holdings Corp. (NVIV), today announced the closing of the exercise of the over-allotment option granted to the underwriters in connection with its previously announced public offering. The underwriters purchased an additional 560,000 shares of InVivo’s common stock, bringing the total proceeds of the offering to approximately $32.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants. In connection with the initial closing of the offering on March 18, 2016, InVivo issued 3,733,333 units at a price of $7.50 per unit, each unit […]

View Article
InVivo Therapeutics to Present at 2016 American Spinal Injury Association Annual Scientific Meeting

Published: March 22, 2016

CAMBRIDGE, Mass. (Mar 22, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Lorianne Masuoka, M.D., Chief Medical Officer, is scheduled to present at the 2016 American Spinal Injury Association (ASIA) Annual Scientific Meeting to be held April 14-16, 2016 in Philadelphia, PA. Dr. Masuoka was invited to present along with several other leaders in the field of spinal cord injury clinical research on April 15th at 3:00 PM (EDT) during the symposium titled “Clinical Trials Update for 2016”. The symposium, organized by the Spinal Cord Outcomes Partnership Endeavor (SCOPE), is intended to appeal to a wide audience of […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.